Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
暂无分享,去创建一个
M. Ogura | K. Tobinai | K. Ando | T. Ishibashi | E. Vandendries | Kiyohiko Hatake | Chiho Ono | Kota Tokushige | Kiyoshi Ando | K. Hatake | Kensei Tobinai | Michinori Ogura | Chiho Ono | Taro Ishibashi | Erik Vandendries | K. Tokushige
[1] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Ogura,et al. Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy , 2010, Cancer science.
[4] M. Czuczman,et al. Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels , 2008, Clinical Cancer Research.
[5] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Giné,et al. Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma. , 2009 .
[7] E. Giné,et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Damle,et al. Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma , 2004, Clinical Cancer Research.
[9] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[10] J. Leonard,et al. Novel agents for follicular lymphoma. , 2010, Hematology. American Society of Hematology. Education Program.
[11] K. Khandke,et al. CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin , 2009 .
[12] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[13] V. Facchinetti,et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. , 2003, Haematologica.
[14] N. Damle,et al. Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma , 2006, Clinical Cancer Research.
[15] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Leonard,et al. Durable complete responses from therapy with combined epratuzumab and rituximab , 2008, Cancer.
[17] J. Leonard,et al. Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.
[18] Boris Gorovits,et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. , 2004, Blood.
[19] M. Czuczman,et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.